These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 28159504)

  • 21. Pharmacists' readiness to provide naloxone in community pharmacies in West Virginia.
    Thornton JD; Lyvers E; Scott VGG; Dwibedi N
    J Am Pharm Assoc (2003); 2017; 57(2S):S12-S18.e4. PubMed ID: 28163027
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The role of managed care pharmacy in coprescribing naloxone for patients with specific risk: recommendations from the AMCP Addiction Advisory Group.
    Skelton JB; Dharbhamalla V
    J Manag Care Spec Pharm; 2022 Jan; 28(1):100-106. PubMed ID: 34949114
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The pharmacist role in the development and implementation of a naloxone prescription program in Alabama.
    Wulz JL; Sung H; Dugan BD; Wensel TM; Lander R; Manzella B
    J Am Pharm Assoc (2003); 2017; 57(2S):S141-S147. PubMed ID: 28209338
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Establishment of a pharmacist-led service for patients at high risk for opioid overdose.
    Tewell R; Edgerton L; Kyle E
    Am J Health Syst Pharm; 2018 Mar; 75(6):376-383. PubMed ID: 29523534
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Emergency department physicians' and pharmacists' perspectives on take-home naloxone.
    Holland TJ; Penm J; Dinh M; Aran S; Chaar B
    Drug Alcohol Rev; 2019 Feb; 38(2):169-176. PubMed ID: 30697852
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacists' knowledge, support, and perceived roles associated with providing naloxone in the community.
    Stewart B; Thomas RL; Tutag-Lehr V
    Curr Pharm Teach Learn; 2018 Aug; 10(8):1013-1021. PubMed ID: 30314535
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacists may dispense new opioid addiction treatment.
    Traynor K
    Am J Health Syst Pharm; 2002 Nov; 59(22):2150, 2152. PubMed ID: 12455298
    [No Abstract]   [Full Text] [Related]  

  • 28. Implementing an overdose education and naloxone distribution program in a health system.
    Devries J; Rafie S; Polston G
    J Am Pharm Assoc (2003); 2017; 57(2S):S154-S160. PubMed ID: 28233681
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A standardized team-based approach for identifying naloxone-eligible patients in a grocery store pharmacy.
    Sexton SM; Armstrong A; Gatton O; Rhodes LA; Marciniak MW
    J Am Pharm Assoc (2003); 2019; 59(4S):S95-S100. PubMed ID: 31231001
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Opioid overdose education and naloxone distribution: Development of the Veterans Health Administration's national program.
    Oliva EM; Christopher MLD; Wells D; Bounthavong M; Harvey M; Himstreet J; Emmendorfer T; Valentino M; Franchi M; Goodman F; Trafton JA;
    J Am Pharm Assoc (2003); 2017; 57(2S):S168-S179.e4. PubMed ID: 28292502
    [TBL] [Abstract][Full Text] [Related]  

  • 31. What is known about community pharmacy supply of naloxone? A scoping review.
    Nielsen S; Van Hout MC
    Int J Drug Policy; 2016 Jun; 32():24-33. PubMed ID: 26949189
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Time for Pharmacy Co-dispensing of Naloxone with Prescribed Opioids?
    Wunderlich JR; Engelberg RS; Tofighi B; Schwartz MD
    J Gen Intern Med; 2022 Aug; 37(11):2621-2623. PubMed ID: 35581455
    [No Abstract]   [Full Text] [Related]  

  • 33. Attitudes and perceptions of naloxone dispensing among a sample of Massachusetts community pharmacy technicians.
    Kurian S; Baloy B; Baird J; Burstein D; Xuan Z; Bratberg J; Tapper A; Walley A; Green TC
    J Am Pharm Assoc (2003); 2019; 59(6):824-831. PubMed ID: 31582224
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Naloxone counseling: Confidence and attitudes of student pharmacists after a volunteer syringe exchange experience.
    Kuryluk V; McAuley J; Maguire M
    Curr Pharm Teach Learn; 2020 Apr; 12(4):429-433. PubMed ID: 32334759
    [TBL] [Abstract][Full Text] [Related]  

  • 35. HMO pharmacy directors' opinions of acquisition of pharmacy benefit management companies.
    Lawrence DB; Weart CW
    Am J Health Syst Pharm; 1995 Jul; 52(14):1547-9. PubMed ID: 7552898
    [No Abstract]   [Full Text] [Related]  

  • 36. Nonprescription naloxone and syringe sales in the midst of opioid overdose and hepatitis C virus epidemics: Massachusetts, 2015.
    Stopka TJ; Donahue A; Hutcheson M; Green TC
    J Am Pharm Assoc (2003); 2017; 57(2S):S34-S44. PubMed ID: 28189540
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacist dispensed naloxone: Knowledge, availability, participation and cost in selected California counties.
    Darracq MA; Lee J; Wilson T; Lasoff D; Armenian P
    Int J Drug Policy; 2019 Sep; 71():113-117. PubMed ID: 31301549
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacists and Naloxone: Barriers to Dispensing and Effectiveness of an Educational Outreach Program.
    Hanson KA; Smart MH; Mandava MR; Carkovic E; Aslamy M; Lee TA; Pickard AS
    J Am Pharm Assoc (2003); 2023; 63(2):608-613.e3. PubMed ID: 36631342
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Student pharmacist perceptions of participation in hands-on naloxone counseling.
    Hines J; Deja E; Black EP
    Curr Pharm Teach Learn; 2018 Jun; 10(6):712-716. PubMed ID: 30025770
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A naloxone and harm reduction educational program across four years of a doctor of pharmacy program.
    Maguire MA; Pavlakos RN; Mehta BH; Schmuhl KK; Beatty SJ
    Curr Pharm Teach Learn; 2018; 10(1):72-77. PubMed ID: 29248078
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.